NCT05613894

Dose-Escalation Study of Cabozantinib in Combination With Lutetium-177 (177Lu)-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer

SUSPENDEDPHASE1INTERVENTIONAL

Trial Details

Start: 2023-07-14Est. Completion: 2026-12

Enrollment target: 33 participants

Locations

Huntsman Cancer Institute at University of Utah, Salt Lake City, Utah, United States

Metastatic Castration-resistant Prostate Cancer (mCRPC)Prostatic Neoplasms

The purpose of this study is to assess the efficacy and safety of opevesostat plus hormone replacement therapy (HRT) com…

Tucson, United StatesEst. completion May 10, 2028

Metastatic Castration-resistant Prostate Cancer

This study is an open-label, multicenter study designed to investigate the efficacy, safety and tolerability of FPI-2265…

Macquarie Park, AustraliaEst. completion May 2027

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.